Full Press Release Details
Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
call begins at 10:00 a.m. Eastern time on Thursday, May16, 2024
MA / ACCESSWIRE / May 15, 2024 / Biofrontera Inc. (Nasdaq:BFRI) (the "Company"), a biopharmaceutical company specializing
in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2024 and provided
from the first quarter of 2024 and subsequent weeks included the following:
| Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breach | ||
| Cash and cash equivalents were $3.8 million as of March 31, 2024, compared with $1.3 million on December 31, 2023 | ||
| The Company completed a private placement of preferred stock with healthcare focused institutional investors for gross proceeds of $8 million | ||
| Met operational and commercial milestones to secure an additional $8 million through the exercise of warrants in connection with the private placement mentioned above | ||
| Renegotiated the Ameluz license and supply agreement (LSA) to reduce the transfer price of Ameluz for 2024 and 2025 from 40 - 50% to 25%, stepping up to 35% by 2032 for Ameluz prescribed in actinic keratosis and non-melanoma skin cancer indications; product costs associated with any acne indication will be 25% indefinitely | ||
| In connection with the LSA amendment, the Company will take over the management and costs of US clinical trials relating to Ameluz on June 1 st , 2024, allowing more direct control and cost management | ||
| The Company anticipates that sales of its new RhodoLED XL lamp will begin in the second quarter of 2024 | ||
| U.S. Food and Drug Administration (FDA) issued a " no filing review issues identified" letter regarding the supplementary New Drug Application submitted by our Ameluz licensor Biofrontera Bioscience GmbH to increase the maximally approved dosage from one to three tubes of Ameluz per treatment. We expect a final decision from the FDA on or around October 4, 2024 |
Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated, "Although
we are disappointed with the decrease in sales during the quarter compared to the same period in 2023, we believe general healthcare
reimbursement issues affecting the entire industry were a major factor. Our team continues to work with insurers and medical providers
to help minimize these challenges. As we have already announced, we have managed to make up the sales shortage and as of April 30th
our 2024 YTD revenue growth is over 5%."
have focused much of our efforts over the last year on developing new accounts and in the first quarter of this year we
placed 29 BF-RhodoLED lamps, an increase of 123% over 1Q 2023, illustrating the need and demand we continue to experience.
We are also looking forward to June 1, 2024, when under the amended LSA we will take control of all clinical trials relating to
Ameluz in the US, allowing for more effective cost management and direct oversight of trial efficiency. The reduced
transfer price will allow us to finance R&D activities and continue our commercial growth trajectory," concluded
Quarter Financial Results
revenues for the first quarter of 2024 were $7.9 million compared with $8.7 million for the first quarter of 2023. The decrease is due
in part to healthcare reimbursement challenges caused by the Change Healthcare data breach that created cash challenges for the entire
health care industry throughout the quarter.
operating expenses were $13.4 million for the first quarter of 2024 compared with $14.2 million for the first quarter of 2023. Cost of
revenues was $4.1 million for the first quarter of 2024 compared with $4.6 million for the prior-year quarter, with the decline driven
by lower sales. Selling, general and administrative expenses were $9.3 million for the first quarter of 2024 compared with $9.8 million
for the first quarter of 2023. The decrease was primarily driven by a $1.1 million decrease in non-recurring legal costs and a decrease
of sales and marketing expenses of $0.3 million. The decrease was primarily offset by a $0.7 million increase in fees and issuance costs
as well as a small increase in personnel expenses.
net loss for the first quarter of 2024 was $10.4 million, or $(2.88) per share, compared with a net loss of $7.5 million, or $(5.60)
per share, for the prior-year quarter. The change in net loss was driven by the revaluation of the B-3 Preferred Warrants, a non-cash
adjustment, along with lower-than-expected sales.
EBITDA for the first quarter of 2024 was negative $4.6 million compared with negative $4.1 million for the first quarter of 2023, reflecting
lower revenues for the first quarter of 2024. We look at Adjusted EBITDA, a non-GAAP financial measure, as a better indication of ongoing
operations and this measurement is defined as net income or loss excluding interest income and expense, income taxes, depreciation and
amortization, and certain other non-recurring or non-cash items.
refer to the table below which presents a GAAP to non- GAAP reconciliation of Adjusted EBITDA for the first quarters of 2024 and 2023.
call: Thursday, May 16, 2024 at 10:00 AM ET
Free: 1-888-222-5806 (U.S. toll-free)
Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological
conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information,
visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.
statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private
Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the Company's
revenue guidance, business and marketing strategy, revenue growth, development and expansion of the Company's sales force and commercial
infrastructure, sales force productivity, growth strategy, liquidity and cash flow, potential to expand the label of Ameluz , available
market opportunities for Ameluz , ongoing clinical trials, educational outreach efforts, and other statements that are not historical
facts. The words "intends," "may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential", "target", "goal", "assume", "would", "could" or
similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. We have based these forward-looking statements on our current expectations and projections about future events; nevertheless,
actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to, our reliance
on sales of products we license from other companies as our sole source of revenue; the success of our competitors in developing generic
topical dermatological products that successfully compete with our licensed products; the success of our principal licensed product,
Ameluz; the ability of the Company's licensors to establish and maintain relationships with contract manufacturers that are able
to supply the Company with enough of the licensed products to meet our demand; the ability of our licensors or their manufacturing partners
to supply the licensed products that we market in sufficient quantities and at acceptable quality and cost levels, and to fully comply
with current good manufacturing practice or other applicable manufacturing regulations; the ability of our Licensors to successfully
defend or enforce patents related to our licensed products; the availability of insurance coverage and medical expense reimbursement
for our licensed products; the impact of legislative and regulatory changes; competition from other pharmaceutical and medical device
companies and existing treatments, such as simple curettage and cryotherapy; the Company's ability to achieve and sustain profitability;
the Company's ability to obtain additional financing as needed to implement its growth strategy; the effect of the COVID-19 global
pandemic; the Company's ability to retain and hire key personnel; and other factors that may be disclosed in the Company's
filings with the Securities and Exchange Commission ("SEC"), which can be obtained on the SEC website at www.sec.gov. Readers
are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and
reflect management's current estimates, projections, expectations and beliefs. The Company does not undertake to update any such
forward-looking statements and expressly disclaims any duty to update the information contained in this press release, except as required
CONSOLIDATED BALANCE SHEETS
thousands, except par value and share amounts)
| March 31, 2024 | December 31, 2023 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,817 | $ | 1,343 | ||||
| Investment, related party | 23 | 78 | ||||||
| Accounts receivable, net | 3,520 | 5,162 | ||||||
| Other receivables, related party | 171 | - | ||||||
| Inventories, net | 6,905 | 10,908 | ||||||
| Prepaid expenses and other current assets | 560 | 425 | ||||||
| Other assets, related party | 5,159 | 5,159 | ||||||
| Total current assets | 20,155 | 23,075 | ||||||
| Property and equipment, net | 120 | 134 | ||||||
| Operating lease right-of-use assets | 1,416 | 1,612 | ||||||
| Intangible asset, net | 2,556 | 2,629 | ||||||
| Other assets | 328 | 482 | ||||||
| Total assets | $ | 24,575 | $ | 27,932 | ||||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 2,717 | 3,308 | ||||||
| Accounts payable, related parties | 4,044 | 5,698 | ||||||
| Operating lease liabilities | 690 | 691 | ||||||
| Accrued expenses and other current liabilities | 4,230 | 4,487 | ||||||
| Short term debt | 2,355 | 3,904 | ||||||
| Total current liabilities | 14,036 | 18,088 | ||||||
| Long-term liabilities: | ||||||||
| Warrant liabilities | 11,731 | 4,210 | ||||||
| Operating lease liabilities, non-current | 621 | 804 | ||||||
| Other liabilities | 33 | 37 | ||||||
| Total liabilities | 26,421 | 23,139 | ||||||
| Commitments and contingencies (Note 17) | ||||||||
| Mezzanine equity: | ||||||||
| Series B-1 Convertible Preferred Stock, $0.001 par value, 6,586 share authorized, 4,806 and zero shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 3,570 | - | ||||||
| Series B-2 Convertible Preferred Stock, $0.001 par value, 6,586 shares authorized, zero shares issued and outstanding as of March 31, 2024 and December 31, 2023 | - | - | ||||||
| Series B-3 Convertible Preferred Stock, $0.001 par value, 8,000 shares authorized, zero shares issued and outstanding as of March 31, 2024 and December 31, 2023 | - | - | ||||||
| Stockholders' equity: | ||||||||
| Preferred Stock, $0.001 par value, 19,978,828 shares authorized, zero shares issued and outstanding as of March 31, 2024 and December 31, 2023 | - | - | ||||||
| Common Stock, $0.001 par value, 15,000,000 shares authorized; 5,089,413 and 1,517,628 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 5 | 2 | ||||||
| Additional paid-in capital | 104,666 | 104,441 | ||||||
| Accumulated deficit | (110,087 | ) | (99,650 | |||||
| Total stockholders' equity | (5,416 | ) | 4,793 | |||||
| Total liabilities, mezzanine equity and stockholders' equity | $ | 24,575 | $ | 27,932 |
CONSOLIDATED STATEMENTS OF OPERATIONS
thousands, except per share amounts and number of shares)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Products revenues, net | $ | 7,901 | $ | 8,715 | ||||
| Revenues, related party | 11 | 18 | ||||||
| Total revenues, net | 7,912 | 8,733 | ||||||
| Operating expenses | ||||||||
| Cost of revenues, related party | 3,946 | 4,547 | ||||||
| Cost of revenues, other | 170 | 51 | ||||||
| Selling, general and administrative | 9,250 | 9,800 | ||||||
| Selling, general and administrative, related party | (4 | ) | 27 | |||||
| Research and development | 17 | - | ||||||
| Change in fair value of contingent consideration | - | (200 | ) | |||||
| Total operating expenses | 13,379 | 14,225 | ||||||
| Loss from operations | (5,467 | ) | (5,492 | ) | ||||
| Other income (expense) | ||||||||
| Change in fair value of warrant liabilities | (3,429 | ) | 1,028 | |||||
| Change in fair value of investment, related party | 3 | (2,941 | ) | |||||
| Loss on debt extinguishment | (316 | ) | - | |||||
| Interest expense, net | (1,407 | ) | (35 | ) | ||||
| Other income (expense), net | 180 | (33 | ) | |||||
| Total other income (expense) | (4,969 | ) | (1,981 | ) | ||||
| Loss before income taxes | (10,436 | ) | (7,473 | ) | ||||
| Income tax expense | 1 | 5 | ||||||
| Net loss | $ | (10,437 | ) | $ | (7,478 | ) | ||
| Loss per common share: | ||||||||
| Basic and diluted | $ | (2.88 | ) | $ | (5.60 | ) | ||
| Weighted-average common shares outstanding: | ||||||||
| Basic and diluted | 3,623,593 | 1,334,950 |
TO NON-GAAP ADJUSTED EBITDA RECONCILIATION
thousands, except per share amounts and number of shares)
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Net loss | $ | (10,437 | ) | $ | (7,478 | ) | ||
| Interest expense, net | 1,407 | 35 | ||||||
| Income tax expenses | 1 | 5 | ||||||
| Depreciation and amortization | 128 | 127 | ||||||
| EBITDA | (8,901 | ) | (7,311 | ) | ||||
| Loss on debt extinguishment | 316 | - | ||||||
| Change in fair value of contingent consideration | - | (200 | ) | |||||
| Change in fair value of warrant liabilities | 3,429 | (1,028 | ) | |||||
| Change in fair value of investment, related party | (3 | ) | 2,941 | |||||
| Legal settlement expenses | - | 1,118 | ||||||
| Stock based compensation | 228 | 351 | ||||||
| Expensed issuance costs | 354 | - | ||||||
| Adjusted EBITDA | $ | (4,577 | ) | $ | (4,129 | ) | ||
| Adjusted EBITDA margin | -57.9 | % | -47.3 | % |